Athira Pharma, Inc. (ATHA) Stock

About Athira Pharma, Inc.

Athira Pharma, Inc., a biopharmaceutical firm in advanced clinical development and based in Bothell, Washington, focuses on creating small molecule treatments designed to revitalize neuronal function and decelerate neurological decline. Its primary therapeutic candidate, ATH-1017, is a unique small molecule that modulates HGF/MET and is capable of crossing the blood-brain barrier. This compound is currently undergoing a Phase 3 clinical trial (LIFT-AD) and a Phase 2 clinical trial (ACT-AD) for Alzheimer's disease. Additionally, ATH-1017 is in Phase 2 clinical trials for Parkinson's disease. The company also has several product candidates in earlier, preclinical stages of development, including ATH-1019 for conditions affecting the peripheral nervous system and ATH-1020 for neuropsychiatric disorders. Founded in 2011, the organization was known as M3 Biotechnology, Inc. until it rebranded to Athira Pharma, Inc. in April 2019.

Athira Pharma, Inc. is headquartered in US.

Athira Pharma, Inc. (ATHA) stock trades at $6.75 with a market capitalization of $26.62M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.28, reflecting a net loss over the last twelve months, price-to-book of 0.73, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.20 and $8.36, and currently trades 19.3% below its 52-week high.

On profitability, Athira Pharma, Inc. generates a return on equity (ROE) of -381.01% (negative, reflecting a net loss), return on capital employed of -170.77%.

Official website: www.athira.com

Athira Pharma, Inc. by the numbers, 2018–2025

Between 2018 and 2025 Athira Pharma, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-106.0M.

On a trailing twelve-month basis to Mar '26, revenue is $0 and net profit $-130.0M.

Borrowings held roughly flat from $1.0M to $1.0M, cash on hand is $67.7M, cash from operations was $-46.0M in the latest year, positive in 0 of the last 8.

Return on equity has averaged -148.6% over five years, and was -378.6% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Athira Pharma, Inc. (ATHA) — frequently asked questions